Playside Studios (ASX: PLY) is not yet profitable, but it is forecasting strong revenue growth.

Alcidion’s CEO Kate Quirke says “we have a very long runway ahead of us” and “at this stage I am confident.”

The Camplify share price failed to respond to the FY 2023 Camplify results, despite very strong revenue growth and positive free cash flow.

A small beat relative to expectations sees a strong share price rise for what is undoubtedly one of the better ASX growth stocks.

Small miss, big sell-off.

Audio networking company Audinate (ASX: AD8) impressed the market with record FY 2023 results. Audinate share price up 10%.

Record revenue, record profits for PWR Holdings (ASX: PWH), but slightly lower margins.

Beacon Lighting (ASX: BLX) offers a decent dividend yield, but may struggle to grow in current conditions.

A review of Sonic Healthcare Ltd (ASX:SHL) FY23 results. Tailwinds are emerging for this defensive market-leading bluechip ASX stock.

The FY 2023 Pro Medicus Results showed record profits and a strengthening competitive advantage, with new products soon to be commercialised.

Carsales.com Ltd (ASX:CAR) results for FY23 were good, but what does its acquisition strategy mean for investor returns going forward?

Acrow Formwork and Constuction Services (ASX: ACF) and Big River Industries (ASX: BRI) trade on low P/E multiples due to the cyclicality of their businesses.

Mach7 (ASX:M7T) ARR has declined slightly and Mach7 missed its operating cash flow guidance in Q4 FY 2023. However, Q1 FY 2024 should be stronger.

Volpara (ASX: VHT) remains close to profitability in Q1 FY 2024, showing good cost control and continuing revenue growth.

Alcidion’s cashflow is heading in the right direction but still no word on when to expect statutory profits.

Record quarterly results cause the Mader Group (ASX: MAD) share price to soar to new highs.

The Audinate share price implies solid growth for years to come, but what should we expect in FY 2023?

The 5th consecutive quarter of positive operating cash flow from Dropsuite was overshadowed by an announcement from Microsoft.

Pathology workflow software stock Beamtree (ASX: BMT) saw its share price fall from almost 20x revenue per share to around 3x.

The Cirrus Networks (ASX: CNW) share price has responded positively to an update on the Cirrus Networks profit result for FY 2023.